Schizophrenia Relapse Clinical Trial
Official title:
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy
To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.
We attempted to reduce the dose of antipsychotics to ≤1000-mg chlorpromazine eq./day. The dose was gradually reduced at a rate of ≤50-mg chlorpromazine eq./week, and the reduction was discontinued if the subjects relapsed. The differences in baseline cognitive function were analyzed between the patients with no relapse and relapse groups. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03090490 -
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Completed |
NCT03558529 -
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
|
||
| Completed |
NCT02220504 -
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Recruiting |
NCT05473741 -
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
|
||
| Completed |
NCT05986409 -
Indoor Artificial Light at Night and the Relapse Risk of Schizophrenia
|
N/A |